亚虹医药: 江苏亚虹医药科技股份有限公司关于公司变更部分董事及调整董事会专门委员会委员的公告

Core Points - Jiang Xinming has resigned from his position as a director and a member of the audit committee of Jiangsu Yahon Pharmaceutical Technology Co., Ltd due to work adjustments, but will continue to hold another position within the company [1][2][3] - The resignation will take effect after the election of a new director at the company's shareholders' meeting, as the current audit committee will have fewer than three members [2][3] - The company expresses gratitude for Jiang Xinming's contributions during his tenure [3] Summary of Changes - Jiang Xinming's resignation details: He held approximately 898,500 shares, representing about 0.16% of the total share capital [3] - Xu Ying has been proposed as a candidate for the board of directors and will serve until the end of the current board's term [3][5] - The audit committee will now include Zhang Binghui as the chairman and members Wang Wenning and Xu Ying [5] Background of New Director - Xu Ying, born in 1968, has extensive experience in the pharmaceutical industry, having held various senior positions in companies such as GlaxoSmithKline and Pfizer [7] - Xu Ying indirectly holds approximately 500,100 shares, accounting for about 0.09% of the total share capital [8] - Xu Ying meets all legal and regulatory requirements to serve as a director and has no disqualifications or negative records [8]